Boundless Bio Q4 net loss $12.9M; cash $107.6M; ceases POTENTIATE enrollment; BBI-940 trial enrolling

Boundless Bio, Inc.

Net loss of $12.9M for Q4 2025 and $58.2M for FY2025, vs $16.4M and $65.4M in same periods of 2024.
Cash, cash equivalents, and short-term investments total $107.6M; expected runway into H2 2028 through initial proof-of-concept readout for KOMODO-1.
Ceased enrollment in Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) due to market considerations and prioritization of BBI-940 program.
KOMODO-1 first-in-human trial of BBI-940 (oral Kinesin degrader) open for enrollment in ER+/HER2- and TNBC-LAR breast cancer.
Director Christine Brennan resigned effective March 3, 2026 due to new role at Johnson & Johnson Development Corp., no disagreement.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Boundless Bio, Inc. reported fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $12.9 million for the fourth quarter of 2025 and $58.2 million for the full year 2025.

Period: fourth quarter and full year ended December 31, 2025
Net income: Net loss totaled $12.9 million for the fourth quarter of 2025 and $58.2 million for the full year 2025
Result: reported results

Exact text from the filing

Net loss totaled $12.9 million for the fourth quarter of 2025 and $58.2 million for the full year 2025, compared to $16.4 million and $65.4 million for the same periods of 2024.

View on SEC.gov

Browse all earnings releases →

Boundless Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-097535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.